shortagewatch

Home / Companies / Baxter

Company family · HQ US

Baxter: medicine shortages

BAX · NYSE

As of 2 Nov 2026, 149 Baxter products have a reported shortage across 12 countries, covering 27 medicines.

Products short149rank #16 of 464
Medicines27active ingredients
Countries12/16
New in 90 days15-10 vs market pace
Typical duration17 monthsmedian so far
Manufacturing63%demand-driven 21%

Where

United States65Canada17Germany16Italy11Spain3Ireland1Austria9Belgium4Switzerland6Czechia5Norway4Sweden8

Which therapeutic classes

Cancer and immune system58Blood38Cardiovascular system18Dermatologicals6Various5Nervous system4Musculoskeletal system4Anti-infectives2Digestive tract and metabolism1Respiratory system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
BaxterBaxter: Manufacturing problem 42 (28%)28%Baxter: Increased demand 14 (9%)9%Baxter: Active ingredient shortage 4 (3%)Baxter: Distribution or logistics 3 (2%)Baxter: Other 3 (2%)Baxter: Not stated 82 (55%)55%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

Latest changes

All changes
DateCountryMedicineChange
1 NovDEMesna
Uromitexan Multidose		resolved

Open shortages over time

3233343531 Oct2026-10-31: 341 Nov2026-11-01: 332 Nov2026-11-02: 33

Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.

When its current shortages began

06121825Dec: 0Jan ’25: 1Feb: 0FebMar: 0Apr: 0May: 0MayJun: 6Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 0NovDec: 4Jan ’26: 23Feb: 10FebMar: 3Apr: 0May: 0MayJun: 10Jul: 1Aug: 6AugSep: 4Oct: 7Nov: 0Nov

Long-run trend in Canada

Canada dashboard
0122537502017: 2020172018: 2320182019: 4820192020: 1920202021: 2920212022: 2620222023: 2620232024: 3620242025: 2020252026: 142026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Baxter149

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Baxter: 149 / 27Baxter

Further right: more products short. Higher: more different medicines affected.

Medicines short

Download CSV
MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Ifosfamide2516 Dec 2025Manufacturing problem12/16
Cyclophosphamide2423 Dec 2025Manufacturing problem12/16
Glucose2014 Feb 2022Not stated1/16
Doxorubicin78 Jun 2026Manufacturing problem8/16
Enoxaparin7not givenNot stated8/16
Clindamycin621 Mar 2023Not stated4/16
Esmolol612 Aug 2024Manufacturing problem6/16
Combinations48 Oct 2026Distribution or logistics1/16
Dexmedetomidine410 Apr 2020Not stated4/16
Dopamine46 Nov 2017Not stated2/16
Dobutamine36 Nov 2017Not stated5/16
Furosemide37 Apr 2020Not stated11/16
Mesna324 Dec 2025Manufacturing problem3/16
Cefazolin22 Jun 2025Active ingredient shortage4/16
Electrolytes21 Jul 2024Increased demand8/16
Heparin214 Nov 2017Increased demand5/16
Ketorolac26 Jun 2018Increased demand4/16
Lidocaine225 Oct 2017Not stated2/16
Rocuronium Bromide215 Feb 2023Not stated5/16
Sugammadex25 Jun 2025Increased demand6/16
Amino Acids121 Sep 2026Not stated5/16
Bendamustine118 Jun 2025Not stated7/16
Calcium Gluconate11 Jan 2025Active ingredient shortage1/16
Mesna131 Aug 2026Other1/16
Metronidazole113 Jan 2022Not stated1/16
Tranexamic Acid15 Jun 2025Increased demand10/16
Trofosfamide13 Sep 2026Manufacturing problem1/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.